A Study to Assess Real-World Use and Outcomes of TAR-200 for Participants With Non-Muscle Invasive Bladder Cancer (NMIBC) in the United States

A Multicenter, Prospective, Longitudinal Study to Assess Real-World Use and Outcomes After the Launch of TAR-200 for NMIBC in the US

The purpose of this study is to assess how well TAR-200 works in real-word by measuring the time taken from the first TAR-200 insertion to worsening of cancer or until the signs and symptoms of cancer occur again (disease-free survival) in participants with non-muscle invasive bladder cancer (NMIBC; an early-stage bladder cancer that is limited to the inner lining of bladder).

Inclusion criteria:

• Has a confirmed diagnosis of NMIBC based on TURBT or cold cup biopsy
• Initiated first dose of TAR-200 in a real-world setting within 6 weeks prior to baseline visit/Study visit 1
• Participants with childbearing potential are required to adhere to contraceptive recommendations as specified in the approved product labeling for TAR-200. Additionally, participants should seek consultation with their physician for personalized contraceptive advice
• Must provide informed consent as described in the protocol

Exclusion criteria:

• Has any medical condition deemed by the health care practitioner (HCP) as contraindicated to receive TAR-200 treatment
• Had previous treatment with TAR-200 discontinued prior to baseline visit/Study visit 1
• Previously received TAR-200 intravesically as part of a clinical trial(s)
• Previously received greater than (>) 2 doses/cycles of TAR-200 in the real-world setting
• Currently participating in an interventional bladder cancer clinical trial